Arvinas Inc. (ARVN) PT Lowered to $20 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)
March 12, 2025 5:28 AM EDTBTIG analyst Jeet Mukherjee reiterated a Buy rating and $69.00 price target on Arvinas Inc. (NASDAQ: ARVN).
The analyst comments "Today, ARVN and partner Pfizer (PFE, NR) reported topline data from the Ph 3 VERITAC-2 trial in ER+/HER2- breast cancer. The study... More
Arvinas Inc. (ARVN) PT Lowered to $10 at Citi
March 11, 2025 3:52 PM EDTCiti analyst Yigal Nochomovitz lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $10.00 (from $19.00) while maintaining a Neutral rating.
The analyst comments "The failure of VERITAC-2 to meet the primary PFS endpoint in the ITT population, driven by the lack of... More
Oppenheimer Downgrades Arvinas Inc. (ARVN) to Perform
March 11, 2025 10:13 AM EDTOppenheimer analyst Matthew Biegler downgraded Arvinas Inc. (NASDAQ: ARVN) from Outperform to Perform.
The analyst comments "Arvinas shares are down sharply today (to ~$9.22) after the company announced that VERITAC-2 had missed on the all-comers co-primary endpoint. The ESR1-mutant co-primary endpoint... More
Arvinas Inc. (ARVN) and Pfizer (PFE) Announce Positive Topline Results from Phase 3 VERITAC-2 Trial
March 11, 2025 6:46 AM EDTArvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.
The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m)... More
